1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Products
2.2. Quantitative Research
2.2.1. Primary and Secondary Products
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Market Breakdown & Data Triangulation
3. Executive Summary
4. United States Genetic Testing Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porters Five Forces Analysis
4.3.1. Bargaining End-use Industry of Suppliers
4.3.2. Bargaining End-use Industry of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Intensity of Rivalry
4.4. Recent Development
4.5. PESTEL Analysis
5. United States Genetic Testing Market Overview
5.1. Market Size & Forecast by Value, 2018-2030
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Type
5.2.1.1. Predictive & Presymptomatic Testing
5.2.1.2. Carrier Testing
5.2.1.3. Prenatal & Newborn Testing
5.2.1.4. Diagnostic Testing
5.2.1.5. Pharmacogenomic Testing
5.2.1.6. Others
5.2.2. By Technique
5.2.2.1. PCR
5.2.2.2. DNA Sequencing
5.2.2.3. Microarrays
5.2.2.4. Others
5.2.3. By Application
5.2.3.1. Cardiology
5.2.3.2. Oncology
5.2.3.3. Pharmacogenomics
5.2.3.4. Cognitive Dysfunction
5.2.3.5. Pathogenomics
5.2.3.6. Others
5.2.4. By End-User
5.2.4.1. Hospitals
5.2.4.2. Independent Laboratories
5.2.4.3. Others
5.2.5. By Payers
5.2.5.1.1. Public Health Insurance
5.2.5.1.2. Private Health Insurance
5.2.5.1.3. Others
6. Competitive Landscape
6.1. List of Key Players and their Offerings
6.2. Company Market Share Analysis, 2021
6.3. Competitive Benchmarking, By Operating Parameters
6.4. Key Strategic Development (Merger, Acquisition, Partnership, etc.)
7. Impact of Covid-19 Across Genetic Testing Market
8. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
8.1. Invitae Corporation
8.2. Ambry Genetics
8.3. Bio Reference Laboratories
8.4. Progenity Inc.
8.5. Quest Diagnostics Incorporated
8.6. Myriad Genetics
8.7. Fulgent Genetics
8.8. Burning Rock Biotech Limited
8.9. Others
9. Key Strategic Recommendations
Note:
Financial information in case of non-listed companies will be provided as per availability
The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable